Clinical Trials Logo

Clinical Trial Summary

The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.


Clinical Trial Description

This study is a single-center, observational, non-interventional, prospective study. 50 patients diagnosed with lung squamous cell carcinoma receiving neoadjuvant chemoimmunotherapy (ranging 2 to 4 cycles) will be planned to be enrolled in the study. Pre-treatment biopsy tissues of enrolled patients will be collected for whole exon sequencing (WES) testing, and personalized detection panel will be customized based on WES testing results. Peripheral blood will be collected 1 day before each cycle of neoadjuvant therapy, 1 day before surgery, 3 days after surgery, and 3 weeks after surgery for ctDNA testing. In addition, the prediction model of AI-based pathology will be constructed by AI deep learning based on pathological sections of pre-treatment biopsy tissues. All inclued patients will be regularly followed up for at least 5 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05778253
Study type Observational
Source Second Xiangya Hospital of Central South University
Contact Yan Hu, M.D., Ph.D.
Phone 8685296122
Email yanhu@csu.edu.cn
Status Recruiting
Phase
Start date March 23, 2023
Completion date September 23, 2029

See also
  Status Clinical Trial Phase
Withdrawn NCT04267913 - Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) Phase 2
Not yet recruiting NCT03725423 - Apatinib for Advanced Lung Squmamous Carcinoma Phase 4
Recruiting NCT06255197 - Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Recruiting NCT04132102 - To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation Phase 4
Active, not recruiting NCT04152018 - Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Phase 1
Recruiting NCT02876978 - Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma Phase 1
Completed NCT01807546 - Oral Rigosertib for Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT01386385 - Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Phase 1/Phase 2
Active, not recruiting NCT00334815 - Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Phase 2
Recruiting NCT05782764 - A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom Phase 4
Recruiting NCT05010330 - Identify Prognostic Biomarkers of Lung Cancer
Recruiting NCT06436040 - Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
Recruiting NCT05024266 - Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma Phase 2
Recruiting NCT04802876 - Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Phase 2